Cancer Research UK appoints leading expert to help accelerate advancements in clinical research

Cancer Research UK announces the appointment of Dr James Larkin as a new Senior Clinical Advisor in clinical research, today.

Dr Larkin’s new role aims to accelerate the progress of the charity’s clinical research portfolio. He will also support the charity in helping ensure the UK can continue to participate in clinical trials across Europe after Brexit.  The role will work alongside Cancer Research UK’s three other Clinical Advisors who specialise in surgery, primary care and children’s cancer.

Dr James Larkin is a consultant medical oncologist and clinical researcher at The Royal Marsden, specialising in the treatment of melanoma and kidney cancer. His research focuses on immunotherapy – using targeted treatments that boost the immune system’s ability to fight cancer.

Dr James Larkin, said: “My focus in this new role will be to ensure the best clinical trials are being run to speed up progress in research and improve treatments for patients. This will include making sure the right infrastructure and training is in place for researchers.”

Professor Charlie Swanton, Cancer Research UK’s chief clinician, said: “I’m delighted that James will be working with Cancer Research UK. We have an ambitious strategy to deliver, including running world class clinical trials in both this country and in the EU. With the current political climate, this timely appointment is essential to ensure patients in the UK and across Europe continue to benefit from collaborative research.”